280 likes | 389 Views
New Reporting Requirements for 2004 Stuart Herna, CTR February 25, 2004. Part I: Collaborative Staging. What is Collaborative Staging? .
E N D
New Reporting Requirements for 2004Stuart Herna, CTRFebruary 25, 2004
What is Collaborative Staging? • Collaborative Staging is a group of data items designed to provide a single uniform set of codes and rules for collecting extent of disease and stage information.
Why A New Coding System? • To collect a unified data set in all registries to report to central agencies • CS uses best available clinical and pathologic data (may be mixed) for staging
When Will CS Go Into Effect? • Implementation Date: • Cases diagnosed on or after January 1, 2004 • NAACCR record layout Version 10.1
Collaborative Staging Data Items • 15 items in data set • 2 existing data items in FCDS data set • Regional Lymph Nodes Positive • Regional Lymph Nodes Examined • 13 new data items
Collaborative Staging Data Items • CS Tumor Size • CS Extension • CS Tumor Size/Ext Eval • CS Lymph Nodes • CS Reg Nodes Eval • Regional LN Examined • Regional LN Positive
Collaborative Staging Data Items • CS Mets At Dx • CS Mets Eval • CS Site-Specific Factor 1 • CS Site-Specific Factor 2 • CS Site-Specific Factor 3 • CS Site-Specific Factor 4 • CS Site-Specific Factor 5 • CS Site-Specific Factor 6
CS Derived Data Items • CS has 12 derived data items • Derived data items are determined every time the computer algorithm is run • Derived fields are viewable only and cannot be changed or edited by the end user • If any CS data item(s) are revised, the CS algorithm must be recalculated to update the Derived CS data items
CS Derived Data Items • Derived AJCC T • Derived AJCC N • Derived AJCC M • Derived AJCC T Descriptor • Derived AJCC N Descriptor • Derived AJCC M Descriptor
CS Derived Data Items • Derived AJCC Stage Group • Derived AJCC Flag • Derived SS1977 • Derived SS1977 Flag • Derived SS2000 • Derived SS2000 Flag
Benefits of Collaborative Staging • Improved efficiency and quality of data • Unified rules • Standardized data set • Standardized training • Stage is derived from objective (factual) data • Accommodates future revisions
Benefits of Collaborative Staging • Addition of TNM stage to FCDS data set • Enhances capability for research • Establishes a uniform data collection standard • Maintains independent objectives of users • Provides Longitudinal stability for epidemiologic and cancer control studies • Allows for data consistency over time
Impact On Registrar • More detailed information to collect but less interpretation • Registrars will not need separate reference manuals in order to assign a stage • Learning curve for new data elements
CS Additional Information • www.training.seer.cancer.gov • http://www.cancerstaging.org/collab.html
Public Law 107-260 • The Benign Brain Tumor Cancer Registries Amendment Act • Public Law 107-260 • Signed by the President October 2002
Reportable Brain-Related Tumors • Public Law 107-260 requires reporting of brain-related tumors • The term ‘brain-related tumor’ means a primary tumor (whether malignant or benign) occurring in any of the following sites: (I) The brain, meninges, spinal cord, cauda equina, a cranial nerve or nerves, or any other part of the central nervous system (II) The pituitary gland, pineal gland, or craniopharyngeal duct
ICD-O-3 Site Codes • C70.0 - C70.9 Meninges • C71.0 - C71.9 Brain • C72.0 - C72.9 Spinal Cord, Cranial Nerves, other CNS • C75.1 Pituitary Gland • C75.2 Craniopharyngeal Duct • C75.3 Pineal Gland
ICD-9-CM Casefinding Codes for Benign and Borderline Intracranial and CNS Tumors
Reporting Requirements • Laterality to be coded for malignant and non- malignant CNS Tumors • C70.0, C71.0, C71.1, C71.2, C71.3, C71.4, C72.2, C72.3, C72.4, and C72.5 • Sequence Numbers (non-malignant) • Are to be sequenced in the range of 60-87
Reporting Requirements • New rules have been created for determining multiple primaries (non-malignant only) based upon: Histology Sub site Laterality
Same Histologic Groupings for Benign/Borderline Brain Tumors • Choroid plexus neoplasms 9390/0, 9390/1 • Ependymomas 9383, 9394, 9444 • Neuronal and neuronal-glial neoplasms 9384, 9412, 9413, 9442, 9505/1, 9506 • Neurofibromas 9540/0, 9540/1, 9541, 9550, 9560/0 • Neurinomatosis 9560/1 • Neurothekeoma 9562 • Neuroma 9570 • Perineurioma, NOS 9571/0
Grade for Non-Malignant Brain and CNS Tumors • The 6th digit of the ICD-O 3 Histology Code describes tumor grade or differentiation - For non-malignant CNS tumors the 6th digit Grade Code is always 9 (not applicable) - The 6th digit ICD-O 3 Grade Code is not the same as the WHO Grade Code
New Edits Software modifications Revision of the Data AcquisitionManual Increased Workload Training/Education Teleconferences Regional Workshops Publications Impact of New Reporting Requirements
Collaborative Staging Manuals • CoC will distribute one set of the Collaborative Staging Manuals to each CoC approved cancer program • FCDS will provide one set of the manuals to all non-approved facilities • Including Ambulatory Patient Care Centers
FCDS Requirements • As of July 1st, 2004, all cases must be submitted in the NAACCR v10.1 record layout. • FCDS will not accept any 2004 cases prior to July 1, 2004. • 2003 cases not reported by the FCDS deadline of June 30, 2004 must be submitted to FCDS in the new NAACCR v10.1 record layout.